DBV Technologies: $229M in Cash to Fund Operations Until Q2 2027
DBV Technologies reports a cash position of $229 million as of March 31, 2026, funded by the full exercise of warrants from the private placement in March 2025. This liquidity position covers the needs until the second quarter of 2027, while the French biotech awaits a critical decision from the US regulator for its pediatric anti-allergen patch.
DBV Technologies has $229 million in cash and cash equivalents as of March 31, 2026. This amount reflects the full exercise of the ABSA and BS warrants from the private placement in March 2025. According to the company, this cash reserve provides funding covering up to the second quarter of 2027 at the current burn rate. The timeline aligns with key milestones in the US regulatory calendar.
Regulatory Milestones Take Precedence Over Operational Results
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Focus is on two imminent milestones. DBV Technologies aims to file a Biologics License Application (BLA) in the first half of 2026 for its VIASKIN Peanut Patch for children aged 4 to 7 years. Concurrently, the company continues its commercial preparations in anticipation of potential market launch in the United States, subject to regulatory approval. This transition phase from clinical stage to commercialization concentrates resources and shapes the company's outlook.
Disciplined Execution Amid Regulatory Risks
DBV Technologies emphasizes a disciplined execution strategy focused on regulatory filing and commercial preparation. The risk profile remains dominated by dependence on US regulatory approval. An unfavorable decision from the FDA could accelerate the consumption of available cash, while approval would initiate an unprecedented commercial cycle for the biotech.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
